Publication date: Mar 21, 2025
This is a randomized, double-blind (60 -79 years) and open-label (40-59 years), three-arm parallel Phase 3b, multicenter study to evaluate the safety and non-inferiority of the humoral immune response of the Butantan Dengue vaccine (Dengue 1,2,3,4 (attenuated)) in participants aged 60 -79 years (elderly) compared to participants aged 40 to 59 years (adults), with or without previous dengue and healthy based on clinical examination.
| Concepts | Keywords |
|---|---|
| Breastfeeding | dengue vaccine |
| Diabetes | elderly population |
| Prnt50 | |
| Professional | |
| Radiotherapy |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | IDO | humoral immune response |
| disease | MESH | Dengue |
| disease | IDO | history |
| disease | IDO | intervention |
| disease | IDO | blood |
| drug | DRUGBANK | Chorionic Gonadotropin (Human) |
| pathway | REACTOME | Immune System |
| disease | MESH | diabetes mellitus |
| disease | MESH | neoplasms |
| disease | MESH | basal cell carcinoma |
| pathway | KEGG | Basal cell carcinoma |
| disease | MESH | AIDS |
| disease | MESH | autoimmune diseases |
| disease | MESH | liver failure |
| disease | MESH | heart failure |
| disease | MESH | chronic kidney disease |
| disease | MESH | psychiatric illness |
| drug | DRUGBANK | Ethanol |
| disease | MESH | allergic reaction |
| disease | MESH | anaphylaxis |
| drug | DRUGBANK | Prednisone |
Original Article
(Visited 1 times, 1 visits today)